Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • ERK
    (13)
  • Apoptosis
    (4)
  • COX
    (3)
  • Ras
    (3)
  • EGFR
    (2)
  • NF-κB
    (2)
  • Akt
    (1)
  • Autophagy
    (1)
  • Bcl-2 Family
    (1)
  • Others
    (8)
Filter
Search Result
Results for "

erk-1/2 inhibitor 2

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    30
    TargetMol | Inhibitors_Agonists
  • Natural Products
    4
    TargetMol | Natural_Products
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
ERK1/2 inhibitor 2
ASTX-029, ASTX029
T84722095719-92-7
ERK1 2 inhibitor 2 (ASTX029) is a selective and orally bioavailable extracellular signal-regulated kinases 1 and 2 (ERK 1 2) inhibitor, with potential antineoplastic activity.
  • Inquiry Price
Size
QTY
Yoda 1
T7506448947-81-7
Yoda 1 is an agonist of the Piezo1 channel that agonizes human- and mouse-derived Piezo1 (EC50=17.1 26.6 μM). Yoda 1 is also an inhibitor of glycine transporter protein 2 (GlyT2).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
ERK1/2 inhibitor 1
T112262095719-90-5In house
ERK1 2 inhibitor 1 is a potent, orally bioavailable compound that exhibits 60% inhibition at 1 nM and has an IC50 of 3.0 nM against ERK1 and ERK2, respectively.
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
XRP44X
XRP-44-X, XRP 44X, XRP-44X, XRP 44 X
T20759729605-21-4In house
XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.
  • Inquiry Price
6-8 weeks
Size
QTY
Rineterkib
ERK-IN-1
T112241715025-32-3
Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1 2 activating mutations in the MAPK pathway.
  • Inquiry Price
10-14 weeks
Size
QTY
ERK-IN-2
T112252743576-56-7
ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and or activity [1].
  • Inquiry Price
8-10 weeks
Size
QTY
CC-90003
T148941621999-82-3
CC-90003 is a selective inhibitor of ERK 1 2. It has antitumor activity.
  • Inquiry Price
Size
QTY
Temuterkib
LY3214996
T40911951483-29-6
Temuterkib (LY3214996) is a potent and selective, orally available inhibitor of the extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity.
  • Inquiry Price
Size
QTY
Butein
2',3,4,4'-tetrahydroxy Chalcone
T6427487-52-5
Butein is a cAMP-specific PDE inhibitor, protein tyrosine kinase inhibitor, and SIRT1 activator. It sensitizes HeLa cells to Cisplatin by targeting FoxO3a via the AKT and ERK p38 MAPK pathways.
  • Inquiry Price
Size
QTY
HM43239
Tuspetinib
T94282294874-49-8
HM43239 is an orally active and selective FLT3 inhibitor with IC 50 s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. HM43239 directly inhibits the kinase activity of FLT3 as a reversible Type I inhibitor and effectively modulates downstream p-STAT5 and p-ERK. HM43239 also demonstrated inhibition of SYK, JAK1 2 and TAK1. HM43239 inhibits the proliferation and induces the apoptosis of leukemic cells [1] [2] [3].
  • Inquiry Price
8-10 weeks
Size
QTY
SC-236
Sc 236
T8505170569-86-5
SC-236 (Sc 236) is an orally active and selective inhibitor of COX-2 (IC50 of 0.005 μM and 17.8 μM for COX-2 and COX-1, respectively).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
SOS1-IN-17
T203656
SOS1-IN-17 (Compound 8d) is an orally active inhibitor targeting the SOS1-KRASG12C interaction, with an IC50 of 5.1 nM. It suppresses ERK phosphorylation in DLD-1 cells with an IC50 of 18 nM and demonstrates antiproliferative activity in KRASG12C-mutant Mia-Paca-2 cells, with an IC50 of 0.11 μM. In mouse models, SOS1-IN-17 shows antitumor efficacy against pancreatic cancer.
  • Inquiry Price
Size
QTY
ERK1/2 inhibitor 12
T204355350509-85-2
ERK1 2 inhibitor 12 (compound 76.3) is an ERK1 2 inhibitor that suppresses ERK-mediated phosphorylation of caspase-9 and p90Rsk-1 kinases. It exhibits anticancer properties and is applicable in cancer research.
  • Inquiry Price
10-14 weeks
Size
QTY
Rineterkib hydrochloride
T366761715025-34-5
Rineterkib hydrochloride (compound B) is an orally active RAF and ERK1 2 inhibitor used in treating proliferative diseases characterized by activating mutations in the MAPK pathway, particularly KRAS-mutant NSCLC, BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC), and KRAS-mutant ovarian cancer[1].
  • Inquiry Price
Size
QTY
Jaceosidin
T382418085-97-7
Jaceosidin has anti-oxidative activity. Jaceosidin has anti-inflammatory activity, also a microglial inhibitor with anti-neuroinflammation activity. aceosidin has anticancer activity, modulates the ERK ATM Chk1 2 pathway, leading to inactivation of the Cd
  • Inquiry Price
Size
QTY
Verrucarin A
T412403148-09-2
Verrucarin A (Muconomycin A) is a Type D macrocyclic mycotoxin. Verrucarin A (VA), derived from the pathogen fungus Myrothecium verrucaria, is a protein synthesis inhibitor that inhibits the growth of leukemia cell lines and activates caspases, apoptosis, and inflammatory signaling in macrophages. It effectively increases the phosphorylation of p38 MAPK and diminishes the phosphorylation of ERK Akt. Additionally, Verrucarin A causes cell cycle deregulation through the induction of p21 and p53 [1] [2].
  • Inquiry Price
10-14 weeks
Size
QTY
CAFESTOL
T5727469-83-0
CAFESTOL is a ERK inhibitor for AP-1-targeted activity against PGE2 production and the mRNA expression of cyclooxygenase (COX)-2 in LPS-activated RAW264.7 cells. Cafestol has strong inhibitory activity on PGE2 production by suppressing the NF-kB activation pathway.
  • Inquiry Price
Size
QTY
kras inhibitor-12
T627512230874-00-5
KRAS inhibitor-12 (compound 6-1) is a potent inhibitor of KRAS G12C (IC50: 0.537 μM), exhibiting p-ERK inhibition in MIA PaCA-2 and A549 cells with IC50 values of 1.3 and 3.7 μM, respectively. KRAS inhibitor-12 has potential for study in pancreatic, colorectal, and lung cancers.
  • Inquiry Price
8-10 weeks
Size
QTY
Calpain-2-IN-1
T63708144231-85-6
Calpain-2-IN-1 is a selective calpain-2 inhibitor that prolongs ERK activation and thus enhances learning and memory.
  • Inquiry Price
6-8 weeks
Size
QTY
multi-kinase-in-2
T639672095628-21-8
Multi-kinase-IN-2 is an orally active inhibitor of angiokinases. multi-kinase-IN-2 significantly inhibits the activity of angiokinases such as VEGFR-1 2 3, PDGFRα β, FGFR-1, LYN and c-KIT kinases. -IN-2 significantly attenuates phosphorylation of AKT and ERK proteins, induces apoptosis and has anticancer effects.
  • Inquiry Price
6-8 weeks
Size
QTY
ERK1/2 inhibitor 3
T743732737294-99-2
ERK1 2 Inhibitor 3, a potent inhibitor of ERK1 2, plays a crucial role in the signal transduction pathway by targeting the Mitogen-activated protein kinase (MAPK) family, specifically the extracellular signal-regulated kinase (ERK). Given its significant impact, this compound holds promise for research or prevention efforts related to cancer, inflammation, or other proliferative diseases[1].
  • Inquiry Price
Size
QTY
ERK1/2 inhibitor 4
T743742490396-99-9
ERK1 2 Inhibitor 5, a potent suppressant of the ERK1 2 pathway, is instrumental in the mitogen-activated protein kinase (MAPK) signal transduction pathway, where extracellular signal-regulated kinase (ERK) serves as a critical component of the MAPK family. This compound holds promise for the investigation or mitigation of cancer, inflammation, or various proliferative diseases[1].
  • Inquiry Price
Size
QTY
ERK1/2 inhibitor 9
T781902169302-75-2
ERK1 2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1 2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates the reduction of phospho-ERK1 2 levels. When conjugated with trans-cyclo-octene (TCO) and Tz-Thalidomide (tetrazine-tagged Thalidomide), it forms the corresponding ERK-CLIPTAC, promoting targeted ERK1 2 degradation [1].
  • Inquiry Price
8-10 weeks
Size
QTY
Paluratide
LUNA18, LUNA 18
T796732676177-63-0
Paluratide (LUNA18) is a reversible cyclic peptide KRAS inhibitor with the advantages of oral availability and cell permeability for the treatment of kras-mutant cancers, which inhibits cancer cell proliferation by phosphorylating ERK and AKT, and also inhibits the interaction of RAS with guanine nucleotide exchange factors (GEFs).
  • Inquiry Price
8-10 weeks
Size
QTY